Pro­mot­ing the Growth of the Cap­i­tal’s Phar­ma­ceu­ti­cal and Health In­dus­tries

Beijing (English) - - CONTENTS - Trans­lated by Wang Wei Edited by Scott Bray Pho­tos by Li Xiaoyin and cour­tesy of the China Beijing Bio­engi­neer­ing and Phar­ma­ceu­ti­cal In­dus­trial Park (CBP)

A se­ries of mea­sures have been taken to fur­ther de­velop Beijing's phar­ma­ceu­ti­cal and health in­dus­tries.

On Oc­to­ber 12, the In­for­ma­tion Of­fice of the Peo­ple's Govern­ment of Beijing Mu­nic­i­pal­ity and the Beijing Mu­nic­i­pal Sci­ence and Tech­nol­ogy Com­mis­sion held a joint press con­fer­ence on the Ac­tion Plan for Ac­cel­er­at­ing the Col­lab­o­ra­tive In­no­va­tion for Beijing's Phar­ma­ceu­ti­cal and Healthy In­dus­tries (2018–2020).

As one of the city's core cut­ting-edge in­dus­tries un­der­go­ing de­vel­op­ment, the phar­ma­ceu­ti­cal and health in­dus­tries play a ma­jor role in fur­ther trans­form­ing Beijing into China's tech­no­log­i­cal in­no­va­tion cen­tre to cre­ate a high-grade ad­vanced eco­nomic struc­ture. The Beijing Mu­nic­i­pal­ity re­leased the Ac­tion Plan to ac­cel­er­ate the de­vel­op­ment of its phar­ma­ceu­ti­cal and health in­dus­tries ac­cord­ing to a num­ber of mea­sures es­tab­lish­ing a col­lab­o­ra­tive in­no­va­tion sys­tem which com­bines the ef­forts of en­ter­prises, uni­ver­si­ties and re­search in­sti­tutes.

De­vel­op­ing Life Sci­ence and Biotech­nol­ogy

Lead­ing trends and break­throughs in global biotech­nol­ogy and life sci­ence trends have be­come a key field in the de­vel­op­ment of the world's sci­ence and tech­nol­ogy. This in turn has en­abled many coun­tries to com­pete with each other to seize the com­mand­ing heights of that growth.

Over the last few years the Cen­tral Govern­ment has pro­mul­gated a num­ber of poli­cies, in­clud­ing the Guid­ing Sug­ges­tion on the De­vel­op­ment of Phar­ma­ceu­ti­cal and Healthy In­dus­tries, to pro­mote growth in the field across the coun­try. Re­gional gov­ern­ments have like­wise for­mu­lated re­spec­tive poli­cies to op­ti­mise their busi­ness cli­mates ac­cord­ing to lo­cal ad­van­tages in re­sources and in­dus­trial char­ac­ter­is­tics.

At the be­gin­ning of the 13th Five-year Plan (2016–2020), Beijing's phar­ma­ceu­ti­cal and health in­dus­tries grad­u­ally grew, with to­tal out­put reach­ing 163.08 bil­lion yuan in 2017, and year-onyear growth of 13 per­cent. At the end of June 2018, to­tal out­put of the in­dus­tries ex­pe­ri­enced a year-on-year growth of nearly 18.4 per­cent, the high­est value af­ter be­gin­ning the 13th Five-year Plan. In so do­ing, the in­dus­tries have reached their tar­get in po­si­tion­ing Beijing as China's tech­no­log­i­cal in­no­va­tion cen­tre.

Faced with ex­cel­lent op­por­tu­ni­ties for de­vel­op­ment along­side ma­jor chal­lenges at home and abroad, the Beijing Mu­nic­i­pal Com­mit­tee of the Com­mu­nist Party of China (CPC) and the Peo­ple's Govern­ment of Beijing Mu­nic­i­pal­ity im­ple­mented a com­pre­hen­sive strat­egy to serve China's na­tional de­vel­op­ment strat­egy and in­te­grate the city's re­sources to pro­mote its 10 in­dus­tries, in­clud­ing phar­ma­ceu­ti­cal and health in­dus­tries. By ad­her­ing to high­qual­ity de­vel­op­ment and re­liev­ing the cap­i­tal of non-es­sen­tial func­tions through its 2017 doc­u­ment, Beijing strives to re­alise its strate­gic po­si­tion­ing and func­tion as China's “four cen­tres”—po­lit­i­cal, cul­tural, in­ter­na­tional ex­change and sci­en­tific and tech­no­log­i­cal in­no­va­tion cen­tre. To im­ple­ment that doc­u­ment, in the be­gin­ning of 2018 the Beijing Mu­nic­i­pal Com­mit­tee of the CPC and the mu­nic­i­pal govern­ment

be­gan to pre­pare a three-year ac­tion plan for col­lab­o­ra­tive in­no­va­tion in the cap­i­tal's phar­ma­ceu­ti­cal and health in­dus­tries. The plan's fo­cus is to over­come crit­i­cal chal­lenges to pro­mote rapid, high qual­ity growth and res­i­dent health­care by util­is­ing the city's tech­no­log­i­cal re­sources and in­dus­trial ad­van­tages.

Propos­ing De­vel­op­ment Goals

The city's Ac­tion Plan fo­cuses on “prob­le­mori­ented so­lu­tions, orig­i­nal in­no­va­tion, com­mer­cial­i­sa­tion of tech­no­log­i­cal achieve­ments and high qual­ity de­vel­op­ment” as its ba­sic prin­ci­ples to put for­ward its de­vel­op­ment goals for the phar­ma­ceu­ti­cal and health in­dus­tries dur­ing the next three years. By 2020, the in­dus­tries' abil­ity to in­no­vate will con­tinue to main­tain the lead­ing po­si­tion in China, its sys­tem of com­mer­cial­is­ing tech­no­log­i­cal achieve­ments op­ti­mised and the pos­i­tive in­flu­ence of its phar­ma­ceu­ti­cal and health in­dus­tries en­hanced. Once the plan is com­plete, a col­lab­o­ra­tive in­no­va­tion sys­tem in­te­grat­ing the ef­forts of en­ter­prises, uni­ver­si­ties and re­search in­sti­tutes will be es­tab­lished and in­dus­trial scope will be fur­ther ex­panded, reach­ing a main busi­ness in­come of 250 bil­lion yuan. With this aim as a driv­ing force, the Ac­tion Plan has set forth 20 ma­jor tasks to achieve th­ese goals.

En­hanc­ing In­no­va­tive Abil­ity

Beijing is a world leader in life sci­ence re­search. There are 70 na­tional-level phar­ma­ceu­ti­cal and health re­search in­sti­tutes in the cap­i­tal, rank­ing first in China. Th­ese in­clude in­sti­tutes that are at­tached to Ts­inghua and Pek­ing uni­ver­si­ties. The city has a wealth of med­i­cal re­sources, in­clud­ing 57 na­tional clin­i­cal test cen­tres, the most in the coun­try. A num­ber of re­search teams led by world- class sci­en­tists such as Wang Xiaodong and Shi Yigong have gath­ered in Beijing, cre­at­ing tech­no­log­i­cal achieve­ments with in­ter­na­tional im­pact. Even so, the city faces chal­lenges with the com­mer­cial­i­sa­tion and in­cu­ba­tion of tech­no­log­i­cal achieve­ments in life sci­ence. There are a scant few types of medicine that be­long to the city's in­de­pen­dent R&D and the Zhong­guan­cun Life Sci­ence Park ser­vice and com­mer­cial­i­sa­tion of tech­no­log­i­cal achieve­ments needs fur­ther im­prove­ment.

To over­come th­ese is­sues, the city is fo­cused on sup­port­ing crit­i­cal ar­eas, strength­en­ing its pro­fes­sional in­cu­ba­tion ca­pac­ity and ac­cel­er­at­ing im­prove­ments to Zhong­guan­cun Life Sci­ence Park; for­mu­lat­ing a de­vel­op­ment plan and a di­rec­tory of its phar­ma­ceu­ti­cal and health col­lab­o­ra­tive in­no­va­tion teams; strength­en­ing ba­sic re­search in­clud­ing struc­tural bi­ol­ogy, syn­thetic bi­ol­ogy, pro­teomics and brain sci­ence; pro­mot­ing stem cell and re­gen­er­a­tive medicine, im­munother­apy, gene de­tec­tion, new se­quenc­ing tech­nol­ogy, multi-mo­dal bio­med­i­cal imag­ing and other ad­vanced tech­nolo­gies; de­vel­op­ing new R&D in­sti­tu­tions and large-scale sci­en­tific equip­ment; en­cour­ag­ing the in­cu­ba­tion of orig­i­nal in­no­va­tive re­sults; pro­mot­ing in­no­va­tive tech­nolo­gies in the pro­duc­tion of ad­vanced med­i­cal ap­pa­ra­tus; in­te­grat­ing phar­ma­ceu­ti­cal and health in­dus­tries with ar­ti­fi­cial in­tel­li­gence and big data in­dus­tries; de­vel­op­ing pro­fes­sional in­cu­ba­tors in the Zhong­guan­cun Life Sci­ence Park and nearby uni­ver­si­ties and med­i­cal in­sti­tu­tions; up­grad­ing the pro­fes­sional ca­pac­ity of ex­ist­ing in­cu­ba­tors; im­prov­ing in­dus­trial parks like Zhong­guan­cun Life Sci­ence Park through the es­tab­lish­ment of a guid­ance com­mit­tee; and in­tro­duc­ing in­ter­na­tional man­age­ment teams to en­hance pro­fes­sional ser­vice sys­tems.

En­hanc­ing Clin­i­cal Re­search

Med­i­cal in­sti­tu­tions and doc­tors are the driv­ing forces sup­port­ing the city's in­no­va­tive de­vel­op­ment in the phar­ma­ceu­ti­cal and health in­dus­tries and play a sig­nif­i­cant sup­port­ing role in the com­mer­cial­i­sa­tion of R&D and eval­u­a­tion and ap­pli­ca­tion of clin­i­cal re­search. Hos­pi­tals should strengthen their goals for clin­i­cal re­search and test­ing, as well as their al­lo­ca­tion of beds, tech­no­log­i­cal teams and in­cen­tive poli­cies. Although the city's hos­pi­tals have be­gun to im­ple­ment pref­er­en­tial poli­cies for en­ter­prises based in Beijing, th­ese poli­cies have yet to meet their needs. To ad­dress this, the city has cre­ated in­no­va­tive prod­ucts on the ba­sis of co­op­er­a­tion be­tween doc­tors and en­ter­prises, but the rate of

com­mer­cial­i­sa­tion of tech­no­log­i­cal re­sults is still not high due to in­suf­fi­cien­cies in hos­pi­tal po­lices. Cen­tring on th­ese ma­jor is­sues, the city has put for­ward four re­form mea­sures to break th­ese bar­ri­ers.

Its first mea­sure aims to im­prove the city's clin­i­cal re­search and test­ing, ac­cel­er­ate the de­vel­op­ment of na­tion­a­land city-level clin­i­cal re­search cen­tres, sup­port med­i­cal in­sti­tu­tions in set­ting up re­search wards, es­tab­lish a test net­work and de­velop in­de­pen­dent clin­i­cal re­search hos­pi­tals.

The sec­ond mea­sure op­ti­mises mech­a­nisms for tech­no­log­i­cal in­no­va­tion within med­i­cal in­sti­tu­tions and es­tab­lishes clin­i­cal re­search and re­sul­tant com­mer­cial­i­sa­tion as a ma­jor ba­sis for the eval­u­a­tion of med­i­cal in­sti­tu­tion per­for­mance and pro­fes­sional ti­tles. Ad­di­tion­ally, de­tailed rules will be in­tro­duced for med­i­cal in­sti­tu­tions to en­cour­age tech­no­log­i­cal in­no­va­tions and their com­mer­cial­i­sa­tion.

The third will guide the city's med­i­cal in­sti­tu­tions in ac­cel­er­at­ing the com­mer­cial­i­sa­tion of their tech­no­log­i­cal achieve­ments, co­op­er­ate with en­ter­prises to de­velop re­search in­sti­tutes to in­no­vate in phar­ma­col­ogy and health, sup­port the com­mer­cial­i­sa­tion of the R& D of clin­i­cal re­search in­sti­tu­tions and set up funds for bring­ing in­dus­try- led in­no­va­tion to mar­ket.

The fourth will pro­mote the shar­ing of med­i­cal and health data and de­velop an open, uni­fied, bi­o­log­i­cal sam­ple li­brary, big data cen­tre and dig­i­tal clin­i­cal re­search net­work.

To fur­ther im­ple­ment the city's Ac­tion Plan, the Beijing Mu­nic­i­pal Com­mis­sion of Health and Fam­ily Plan­ning and Beijing Mu­nic­i­pal Ad­min­is­tra­tion of Hos­pi­tals will fo­cus on the fol­low­ing tasks: in­creas­ing in­vest­ment to im­prove in­sti­tu­tional clin­i­cal re­search and tests within Beijing, de­vel­op­ing a new clin­i­cal re­search sys­tem in ac­cor­dance with in­ter­na­tional stan­dards and strength­en­ing the pos­i­tive in­flu­ence of the city's med­i­cal and health in­sti­tu­tions.

De­vel­op­ing Ma­jor En­ter­prises

Beijing's phar­ma­ceu­ti­cal and health in­dus­tries need to grow and their out­put brought to a higher level. In or­der to ac­com­plish this, the city should fo­cus on sup­port­ing large, in­no­va­tive en­ter­prises to pro­mote growth within the in­dus­try.

To en­sure its mea­sures are ef­fec­tive, Beijing as­sists dif­fer­ent types of en­ter­prises in solv­ing re­spec­tive de­vel­op­ment is­sues. For ex­am­ple, re­search-ori­ented en­ter­prises typ­i­cally en­counter prob­lems like a dif­fi­cult ap­proval process for their pro­duc­tion lines, while pro­duc­tion-ori­ented en­ter­prises face is­sues such as in­suf­fi­cient in­vest­ment for their R&D due to their small scale, and have pro­duc­tion lines that lack op­ti­mi­sa­tion and are not glob­alised. Like­wise, third-party ser­vice providers are lack­ing tech­ni­cal ser­vices and in­ter­na­tion­al­i­sa­tion. More­over, the city's pi­lot and pro­duc­tion plat­forms are still lag­ging be­hind with the in­dus­tri­al­i­sa­tion of in­no­va­tive prod­ucts, and ser­vice plat­forms that com­ply with in­ter­na­tional stan­dards for biosim­i­lars tests are es­pe­cially lack­ing. To meet a va­ri­ety of needs, the city has pro­mul­gated seven sub­stan­tive mea­sures to re­solve the dif­fi­cul­ties of its phar­ma­ceu­ti­cal and health en­ter­prises.

Strength­en­ing one-stop and track­ing ser­vices for the city's ma­jor phar­ma­ceu­ti­cal and health en­ter­prises solves a va­ri­ety of is­sues en­coun­tered dur­ing R&D, pro­duc­tion and op­er­a­tion un­der the city's prin­ci­ple of “one en­ter­prise, one pol­icy, one is­sue, one so­lu­tion.”

For R&D en­ter­prises, an ap­proval chan­nel will be es­tab­lished for in­no­va­tive prod­ucts to ac­cel­er­ate clin­i­cal tests. Af­ter said R&D ma­tures, sup­port in the de­vel­op­ment of ad­vanced prod­uct lines will re­alise the com­mer­cial­i­sa­tion and large-scale pro­duc­tion of their tech­no­log­i­cal achieve­ments.

For pro­duc­tion-ori­ented en­ter­prises, the city will aim to up­grade pro­duc­tion lines to ex­pand pro­duc­tion, re-de­velop ma­jor prod­ucts and ex­plore in­ter­na­tional mar­kets, carry out fi­nanc­ing for go­ing pub­lic, merg­ers and ac­qui­si­tions and pro­vide other sup­port.

For third- party ser­vice providers to th­ese en­ter­prises, the city will pro­vide stan­dard­ised in­ter­na­tional cer­ti­fi­ca­tion, funds, land, fac­to­ries and other favourable con­di­tions.

In the Haid­ian and Chang­ping dis­tricts, ser­vice plat­forms for biosim­i­lars tests, each of which will reach 1,000 litres, will be de­vel­oped, along­side a 100,000-litre pro­duc­tion line in an eco­nomic and tech­no­log­i­cal de­vel­op­ment area to ac­cel­er­ate the pro­duc­tion and pro­fes­sional ser­vices in the

phar­ma­ceu­ti­cal and health in­dus­tries.

Sup­port for the de­vel­op­ment of multi­na­tional com­pa­nies in Beijing oper­ates in lock­step with the world's lead­ing phar­ma­ceu­ti­cal and health com­pa­nies, en­cour­ag­ing such en­ter­prises to set up head­quar­ters and R&D cen­tres in the city.

In­te­grat­ing the city's re­sources of tra­di­tional Chi­nese medicine ( TCM) from col­leges and in­sti­tu­tions will also pro­mote in­no­va­tion and de­vel­op­ment within the TCM in­dus­try, and will help lead en­ter­prises in the field by com­bin­ing TCM the­ory with mod­ern sci­ence and tech­nol­ogy while strength­en­ing TCM re­search.

Op­ti­mis­ing Busi­ness En­vi­ron­ment

Cer­tain fac­tors in the cur­rent de­vel­op­ment of Beijing's phar­ma­ceu­ti­cal and health in­dus­tries are still lack­ing. In turn, in­no­va­tion, pro­duc­tion, fund­ing and in­dus­try poli­cies have room for fur­ther im­prove­ment, and the clin­i­cal ap­pli­ca­tion of new prod­ucts and in­dus­tri­al­i­sa­tion of R&D still need to be op­ti­mised. The city will fo­cus on six mea­sures to cre­ate favourable con­di­tions for in­no­va­tion and start-ups within the phar­ma­ceu­ti­cal and health in­dus­tries.

Pro­mot­ing the in­te­grated de­vel­op­ment of the city's phar­ma­ceu­ti­cal and health in­dus­tries will re­quire ac­cel­er­at­ing the city's in­dus­trial lay­out and en­sur­ing ad­di­tional new spa­ces in dis­tricts where th­ese in­dus­tries are key play­ers. Haid­ian and Chang­ping dis­tricts in par­tic­u­lar need to take ad­van­tage of the ba­sic re­search and cut­ting-edge tech­nolo­gies in this field, while new spa­ces in Dax­ing Dis­trict and the Beijing Eco­nomic-tech­no­log­i­cal De­vel­op­ment Area are ideal in in­dus­try de­vel­op­ment and fur­ther en­hanc­ing ad­van­tages held in high-end man­u­fac­tur­ing.

The op­ti­mi­sa­tion and en­hance­ment of in­dus­trial parks ser­vices within Beijing in­cludes im­prov­ing the en­try in­spec­tion and quar­an­tine of bi­o­log­i­cal ma­te­ri­als in Zhong­guan­cun Life Sci­ence Park and a one-stop pub­lic ser­vice plat­form for en­try-exit clear­ance for the bi­o­log­i­cal reagent im­port and ex­port lo­gis­tics cen­tre in the Beijing Eco­nomic-tech­no­log­i­cal De­vel­op­ment Area.

Prepa­ra­tions for an eval­u­a­tion stan­dard and ac­cred­i­ta­tion pro­ce­dure for new phar­ma­ceu­ti­cal and health prod­ucts and tech­nolo­gies that form a cat­a­logue en­cour­ages med­i­cal in­sti­tu­tions un­der the city's ju­ris­dic­tion to carry out list­based pro­cure­ment.

The price man­age­ment of new med­i­cal ser­vices will be op­ti­mised and de­tailed rules for the price man­age­ment of the city's new ser­vices pro­vided by the city's pub­lic med­i­cal in­sti­tu­tions will be pre­pared to ex­plore the im­ple­men­ta­tion of dy­namic man­age­ment in this field.

Ac­cord­ing to the State Coun­cil of China's re­quire­ments, the city needs to pre­pare for and im­ple­ment a per­mit sys­tem for medicines to en­ter the mar­ket, in­crease in­cen­tives to en­cour­age in­no­va­tion in phar­ma­ceu­ti­cal and health en­ter­prises in­clud­ing pro­vid­ing in­cen­tives for the en­ter­prises reach­ing cer­tain met­rics re­gard­ing an­nual in­come, gain­ing ap­proval for ma­jor in­no­va­tive prod­ucts to en­ter do­mes­tic and in­ter­na­tional mar­kets, and re­ceiv­ing con­form­ity prod­uct as­sess­ments at home and abroad.

Sup­port­ing the City’s Phar­ma­ceu­ti­cal and Health In­dus­tries

To en­sure the im­ple­men­ta­tion of the tasks laid out above, the Ac­tion Plan puts for­ward a four-facet guar­an­tee sys­tem. First, it will strengthen over­all plan­ning and set up a joint con­fer­ence sys­tem led by mu­nic­i­pal govern­ment lead­ers to pro­mote col­lab­o­ra­tive in­no­va­tion within the city's phar­ma­ceu­ti­cal and health in­dus­tries; sec­ond, mu­nic­i­pal govern­ment de­part­ments and rel­e­vant dis­trict gov­ern­ments shall for­mu­late sup­port­ing poli­cies and mea­sures and de­tailed pro­grammes in ac­cor­dance with the

Ac­tion Plan; third, hu­man re­source sup­port will be strength­ened and top tal­ent with in­ter­na­tional in­flu­ence will con­tinue to be in­tro­duced and aided in the city; and fourth, fi­nan­cial sup­port will be en­sured to act as govern­ment fund­ing and so­cial cap­i­tal.

Ac­cord­ing to the guid­ing prin­ci­ple of the 19th Na­tional Congress of the CPC and the re­quire­ments of the Cen­tral Eco­nomic Work­ing Con­fer­ence, the next step for the city to take is im­ple­men­ta­tion of ma­jor tasks by rel­e­vant de­part­ments of the mu­nic­i­pal govern­ment as re­quired by the Ac­tion Plan. By at­tract­ing top tal­ent and de­vel­op­ing a co­op­er­a­tive mech­a­nism to im­prove growth fac­tors for the city's phar­ma­ceu­ti­cal and health in­dus­tries, fur­ther de­vel­op­ment of Beijing as China's tech­no­log­i­cal in­no­va­tion cen­tre will be ac­cel­er­ated, ex­ert­ing global in­flu­ence as it forms its high- grade, high-pre­ci­sion ad­vanced eco­nomic struc­ture.

Beijing Tiantan Hos­pi­tal

A doc­tor ex­am­in­ing CT scans

China Beijing Bio­engi­neer­ing and Phar­ma­ceu­ti­cal In­dus­trial Park (CBP) in Dax­ing

Two nurses pre­par­ing medicine

Newspapers in English

Newspapers from China

© PressReader. All rights reserved.